Who is sponsoring NCT00660036?

NCT00660036 is sponsored by University of Pittsburgh.

What condition does NCT00660036 study?

NCT00660036 studies Acute Myeloid Leukemia.

What drugs are being tested in NCT00660036?

Interventions: Gemtuzumab ozogamicin, Mitoxantrone, Etoposide.

What is the status of NCT00660036?

NCT00660036 is currently TERMINATED.

Last reviewed 2016-01-14 · How we verify

Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154)

NCT00660036 Phase 1 TERMINATED

The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia.

Details

Lead sponsor	University of Pittsburgh
Phase	Phase 1
Status	TERMINATED
Enrolment	5
Start date	2008-09
Completion	2011-04

Conditions

Acute Myeloid Leukemia

Interventions

Gemtuzumab ozogamicin
Mitoxantrone
Etoposide

Primary outcomes

To evaluate the toxicity and response rate of the combination therapy of mitoxantrone, etoposide and gemtuzumab ozogamicin as second line therapy in patients with acute myeloid leukemia (AML). — Bone marrow biopsy and aspiration 14 days after gemtuzumab ozogamicin administration, to evaluate response to the study drug regimen.

Countries

United States